| |
New investments in health tech have set the stage for industry players and revolutionary AI in imaging, drug discovery, digital therapeutics, and more.
Download our whitepaper for trends industry experts believe will shape the virtual care landscape.
|
|
Today’s Big NewsSep 29, 2023 |
| By Zoey Becker Fabre-Kramer's Exxua suffered three prior FDA rejections before scoring an FDA approval for major depressive disorder last week. Its label doesn't include sexual dysfunction as an adverse reaction, which is rare among antidepressants. |
|
|
|
By Nick Paul Taylor Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. |
By Conor Hale The FDA has put forward its official pitch for regulating laboratory-developed tests, a long-awaited proposal that would bring those products more in line with how the agency approaches other in vitro diagnostics. |
By James Waldron PTC Therapeutics has announced that its layoffs will now go deeper and wider than previously announced as European regulators consider halting sales of the company’s Duchenne muscular dystrophy drug. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now.
|
|
By Kevin Dunleavy Teva Pharmaceuticals' new CEO Richard Francis has continued his transformation of the Israeli company, bringing on Christine Fox as the new head of its U.S. commercial business, replacing 15-year Teva veteran Sven Dethlefs, who departs Nov. 17. Fox arrives from Novartis, where she has been the global president of gene therapies for nearly two years. |
By Andrea Park They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. |
By Nick Paul Taylor Adlai Nortye has established the financial foundation to show whether its bet on an ex-Novartis asset will pay off, securing $97.5 million through an IPO and private placement to fund a phase 3 trial in head and neck cancer. |
By Andrea Park According to Exo, the Iris system is designed to replace traditional cart-based ultrasound mechanisms with a simple handheld probe, which connects to a smartphone to display its captured images. |
By Fraiser Kansteiner After a former human resources officer blew the whistle on alleged manufacturing shortfalls at Eli Lilly’s massive Branchburg, New Jersey, production plant, the parties have been engaged in settlement talks. |
By Max Bayer ModeX Therapeutics has won a BARDA contract worth up to $168 to develop next-gen antibodies against viral infection. The company inked a partnership with Merck earlier this year worth more than $800 million. |
By Fraiser Kansteiner A proposed restriction on the use of fluorinated substances in Europe would have an “irredeemable impact” on the continent’s life sciences sector, the European Federation of Pharmaceutical Industries and Associations (EFPIA) warns. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions. |
|
|---|
|
|
|
Thursday, October 5, 2023 | 11am ET / 8am PT Viral vectors used in gene therapies face complex and multifaceted analytical challenges. Developing standardized and validated analytical methods, reference standards, and reagents are critical to overcoming these challenges. Join us to learn how to accelerate the development and translation of safe and effective viral vector-based gene therapies with next-generation analytics. Register now.
|
|
| eBookLearn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
| Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperLearn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
